RSS Subscribe to our Nanotechnology Business News feed

Tekmira Pharmaceuticals Receives Key Patents for Lipid Nanoparticle Technology

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents covering elements of Tekmira's leading lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).

Nov 25th, 2010

Read more